Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-3167 vs Insulin Glargine in Type 2 Diabetes
NCT06688123Phase 2Completed
- Sponsor
- Hengrui
- Start
- Jan 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SHR-3167 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hengrui. Primary endpoint: Change from baseline in Hemoglobin A1c at 20 weeks. Started Jan 2025; status: completed.
02
Drugs
SHR-3167
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06688123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06688123.